FBIO vs ROIV

For growth investors, Roivant Sciences Ltd.

(ROIV) is the stronger pick with -11. 2% revenue growth year-over-year, versus -31. 8% for Fortress Biotech, Inc. (FBIO). Analysts rate Fortress Biotech, Inc. (FBIO) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Roivant Sciences Ltd.

(ROIV) delivered a total return of +190. 8%, compared to -95. 6% for Fortress Biotech, Inc. (FBIO). Over 10 years, the gap is even starker: ROIV returned +177. 1% versus FBIO's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Roivant Sciences Ltd.

(ROIV) is the lower-risk stock at 0. 95β versus Fortress Biotech, Inc. 's 0. 97β — meaning FBIO is approximately 2% more volatile than ROIV relative to the S&P 500.

By revenue growth (latest reported year), Roivant Sciences Ltd.

(ROIV) is pulling ahead at -11. 2% versus -31. 8% for Fortress Biotech, Inc. (FBIO). On earnings-per-share growth, the picture is similar: Fortress Biotech, Inc. grew EPS 68. 2% year-over-year, compared to -104. 6% for Roivant Sciences Ltd.. Over a 3-year CAGR, FBIO leads at -5. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Fortress Biotech, Inc.

(FBIO) is the more profitable company, earning -79. 8% net margin versus -592. 0% for Roivant Sciences Ltd. — meaning it keeps -79. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBIO leads at -191. 4% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — ROIV leads at 96. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, FBIO (1.

3% yield) pays a dividend. ROIV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Fortress Biotech, Inc.

(FBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97), 1. 3% yield). Both have compounded well over 10 years (FBIO: -94. 3%, ROIV: +177. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

FBIO pays a dividend while ROIV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.